Results 61 to 70 of about 12,742 (223)

Effect of oxidative stress on ABC transporters: contribution to epilepsy pharmacoresistance [PDF]

, 2017
Epilepsy is a neurological disorder affecting around 1%-2% of population worldwide and its treatment includes use of antiepileptic drugs to control seizures. Failure to respond to antiepileptic drug therapy is a major clinical problem and over expression
Grewal, G. K., Kanojia, N., Kukal, S., Kukreti, R., Kukreti, S., Saso, L.   +5 more
core   +2 more sources

Did the French pregnancy pictogram change antiseizure medication use during pregnancy?

Epilepsia, EarlyView.
Abstract Objective The aim of this study was to assess the impact of introducing a pregnancy pictogram on medication packaging on the prescription and dispensation of antiseizure medications and on the maternal and neonatal outcomes for women exposed to these medications.
Mélanie Araujo, Christine Damase‐Michel, Marie Denuelle, Sébastien Boulogne, Laurane Delteil, Monica Saucedo, Catherine Deneux‐Tharaux, Isabelle Lacroix   +7 more
wiley   +1 more source

Zonisamide Ameliorated the Apoptosis and Inflammation in Cerebellar Tissue of Induced Alcohol Addiction Animal Model

Life
This study investigated the effects of zonisamide treatment on cerebellar tissues in an experimental alcohol addiction (AA) model and its potential mechanisms of action, particularly regarding apoptotic protease activating factor-1 (APAF-1) and tumor ...
Fırat Aşır, Fikri Erdemci, Zuhal Çankırı, Tuğcan Korak, Süreyya Özdemir Başaran, Özge Kaplan, Özkan Yükselmiş, Nilüfer Dönmezdil, Hayat Ayaz, Şehmus Kaplan, Selçuk Tunik   +10 more
doaj   +1 more source

How Can Network-Pharmacology Contribute to Antiepileptic Drug Development? [PDF]

, 2014
Network-pharmacology is a field of pharmacology emerging from the observation that most clinical drugs have multiple targets, contrasting with the previously dominant magic bullet paradigm which proposed the search of exquisitely selective drugs. What is
Di Ianni, Mauricio Emiliano, Talevi, Alan   +1 more
core   +1 more source

Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics [PDF]

, 2012
Introduction: In order to assess the significance of drug levels measured in intensive care medicine, clinical and forensic toxicology, as well as for therapeutic drug monitoring, it is essential that a comprehensive collection of data is readily ...
Andresen, Hilke, Iwersen-Bergmann, Stefanie, Schmoldt, Achim, Schulz, Martin   +3 more
core   +1 more source

Sleep magnetoencephalography enhances detection and source imaging of seizures and fast oscillations in focal cortical dysplasia

Epilepsia, EarlyView.
Abstract Objective Focal cortical dysplasia (FCD) causes drug‐resistant epilepsy requiring presurgical evaluation. Invasive electroencephalographic (EEG) studies demonstrate that sleep modulates epileptic activity, including interictal epileptiform discharges (IEDs), fast oscillations (FOs) in the beta (14–40 Hz) and gamma (40–80 Hz) frequency bands ...
Marcel Heers, Jawata Afnan, Christoph Braun, Christophe Grova, Dirk‐Matthias Altenmüller, Bernhard J. Steinhoff, Matthias Dümpelmann, Theo Demerath, Horst Urbach, Silke Ethofer, Markus Siegel, Andreas Schulze‐Bonhage, Holger Lerche, Yiwen Li Hegner   +13 more
wiley   +1 more source

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]

, 2015
OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria, Lafortune, Louise, Mak, Elijah, Mason, James, McKeith, Ian, Mioshi, Eneida, O'Brien, John T, Stinton, Chris, Taylor, John-Paul, Thomas, Alan   +9 more
core   +2 more sources

Women with epilepsy: Evidence‐based counseling across the lifespan

Epilepsia, EarlyView.
Abstract Women with epilepsy (WWE) encounter distinct and evolving challenges across the lifespan that require clinical management extending beyond seizure control alone. Although awareness of sex‐specific aspects of epilepsy has increased, important gaps remain in their integration into routine care.
Barbara Tettenborn, Georgia Ramantani, Dominique Flügel, Verena Gaus, Susanne Schubert‐Bast, Elisabeth Sellitto, Jennifer Bausch, Bettina Schmitz   +7 more
wiley   +1 more source

The ongoing pursuit of neuroprotective therapies in Parkinson disease [PDF]

, 2015
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD.
A Alonso, A Ascherio, A Consoli, A Fitton, A Goris, A Harkavyi, A Schneeberger, A Schneider, A Zimran, A-L Mougenot, AD Wahner, AE Berman, AE Lang, AH Schapira, AHV Schapira, AHV Schapira, AL Bartels, AR Carta, AR Diani, B Pasternak, B Ritz, B Ritz, B Schütz, B Wolozin, B Zhang, BI Pérez-Revuelta, BJ Snow, C Becker, C Becker, C Hansen, C Marras, C Pifl, C Shen, C Stack, CD Ward, CM Wischik, CR Swanson, CS Chan, CS Chan, CW Olanow, CW Olanow, CW Olanow, CW Olanow, CY Chung, D Aarsland, D Devos, D Muslimovic, D Tsuang, D-K Choi, D-P Hong, DD Lofrumento, DF Tardiff, DG Parkes, Dilan Athauda, DJ Irwin, DJ Irwin, DT Dexter, DT Dexter, E Andreadou, E Bezard, E Ilijic, E Masliah, E Masliah, E Masliah, EC Hirsch, F Blandini, F Molina-Holgado, F Richter, FL Martin, FL Watson, G Bertilsson, G Costa, G Tóth, G Wu, GJ Ryan, GK Ulusoy, GW Duncan, H Braak, H Jin, H Mortiboys, HI Hurtig, I Aviles-Olmos, I Aviles-Olmos, I Bendikov-Bar, I Pedroso, J Clark, J Hippisley-Cox, J Neumann, J Pan, J Sian, J Sian-Hülsmann, J Simón-Sánchez, J Yan, J-H Kang, J-Y Li, JA Posener, JC Adair, JC O'Leary, JF Morley, JH Kordower, JJ Elm, JM Fearnley, JP Anderson, JR Colca, JR Colca, JR Colca, JS Schneider, JS Schneider, JS Schneider, JW Steele, K Imamura, K Meuer, K Okada, K Parain, K-H Jung, K-W Lee, KA Jellinger, KC Luk, L Azoulay, LA Volpicelli-Daley, LS Tain, M Asanuma, M Broadstock, M Ferwana, M Katz, M Murata, M Okada, M Quik, M Quik, M Santiago, M Selikhova, M Takanashi, MA Hely, MA Nunes, MA Schwarzschild, MA Schwarzschild, MC Hernández-Romero, ME Choudhury, ME Choudhury, MF Beal, MF Beal, MG Weisskopf, MI Ekstrand, MJ Hurley, ML Selley, ML Wahlqvist, MM Iravani, MM Khan, MT Heneka, N Boddaert, N Rampersaud, NP Visanji, O Weinreb, P Bar-On, P Brundin, P Desplats, P Riederer, P Schwingenschuh, PA Agarwal, PC Grayson, PN Tariot, PT Kotzbauer, Q Wang, R Crichton, R Duran, R Haddadi, RA Hauser, RA Hauser, RA Lawson, RB D'Agostino, RC Chang, RE Ryan, RJ Ward, S Chen, S Duty, S Fahn, S Kang, S Kim, S Mochio, S Mounayar, S Pålhagen, S Shimohama, S Suzuki, S-T Lee, SH Appel, SJ Chinta, SP Sardi, SS Jamuar, T Breidert, T Dehmer, T Foltynie, T Foltynie, T Foltynie, T Hartung, T Nakamura, T Perry, T Perry, T Yamamoto, TB Sherer, Thomas Foltynie, TJ Montine, TL Edwards, TL Spires-Jones, V Dragalin, VA Yürekli, W Jang, WJ Marks, X Chen, X Gao, X Huang, X Zhang, Y Compta, Y Wen, Y-C Lee, Y-Q Xue, ZI Alam   +215 more
core   +1 more source

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add‐on trials in drug‐resistant focal epilepsy

Epilepsia, EarlyView.
Abstract Objective Most antiseizure medications (ASMs) have been discovered by testing in animal models, which are generally thought to predict antiseizure activity in patients. However, it is not known whether any of these models (or a combination of models) can predict whether a novel ASM exhibits higher clinical efficacy in focal drug‐resistant ...
Wolfgang Löscher, Pavel Klein
wiley   +1 more source